The bleeding time

Platelets

Volumn , Issue , 2007, Pages 485-493

  Lind, Stuart E ^a   Kurkjian, Carla D ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33751090661     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50787-4     Document Type: Chapter

References (87)

1. Milian M.G. Technique pour l'etude clinique de la coagulation du sang. Soc Med Hosp Paris 1901, 18:777-779.
2. Lehman C.M., Rodgers G.M. Abolition of the bleeding time test at an academic medical center. Blood 2000, 96:436a.
3. Bowie E.J., Owen C.A. The bleeding time. Prog Hemost Thromb 1974, 2:249-271.
4. Spaet T.H. Platelets: The blood dust. Blood, pure and eloquent 1980, 548-571. McGraw-Hill, New York. M.M. Wintrobe (Ed.).
5. Duke W.W. The relation of blood platelets to hemorrhagic disease. JAMA 1910, 60:1185-1192.
6. Brinkhous K.M. W. W. Duke and his bleeding time test. A commentary on platelet function. JAMA 1983, 250:1210-1214.
7. Sutor A.H., Bowie E.J., Owen C.A. Quantitative bleeding time (hemorrhagometry). A review. Mayo Clin Proc 1977, 52:238-240.
8. Schwartz B.S., Leis L.A., Johnson G.J. In vivo platelet retention in human bleeding-time wounds. Ii. Effect of aspirin ingestion. J Lab Clin Med 1979, 94:574-584.
9. Abrams C.S., Ellison N., Budzynski A.Z., et al. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990, 75:128-138.
10. De Caterina R., Lanza M., Manca G., et al. Bleeding time and bleeding: An analysis of the relationship of the bleeding time test with parameters of surgical bleeding. Blood 1994, 84:3363-3370.
11. Ivy A.C., Shapiro P.F., Melnick P. The bleeding tendency in jaundice. Surg Gynecol Obstet 1935, 60:781-784.
12. McNealy R.W., Shapiro P.F., Melnick P. The effect of viosterol in jaundice. Surg Gynecol Obstet 1935, 60:785-801.
13. Tocantins L.M. The bleeding time. Am J Clin Path 1936, 6:160-171.
14. Mielke C.H., Kaneshiro M.M., Maher I.A., et al. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969, 34:204-215.
15. Harker L.A., Slichter S.J. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972, 287:155-159.
16. Harker L.A., Malpass T.W., Branson H.E., et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha-granule. Blood 1980, 56:824-834.
17. Abildgaard C.F., Suzucki Z., Harrison J., et al. Serial studies in von Willebrand's disease: Variability versus "variants. Blood 1980, 56:712-716.
18. Lind S.E. Prolonged bleeding time. Am J Med 1984, 77:305-312.
19. Barber A., Green D., Galluzzo T., et al. The bleeding time as a preoperative screening test. Am J Med 1985, 78:761-764.
20. Burns E.R., Lawrence C. Bleeding time. A guide to its diagnostic and clinical utility [see comments]. Arch Pathol Lab Med 1989, 113:1219-1224.
21. Triplett D.A. The bleeding time. Neither pariah or panacea [editorial; comment]. Arch Pathol Lab Med 1989, 113:1207-1208.
22. Rodgers R.P., Levin J. A critical reappraisal of the bleeding time. Sem Thromb Hemost 1990, 16:1-20.
23. Lind S.E. The bleeding time does not predict surgical bleeding. Blood 1991, 77:2547-2552.
24. Bernardi M.M., Califf R.M., Kleiman N., et al. Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAM. Am J Cardiol 1993, 72:1121-1125.
25. Gewirtz A.S., Miller M.L., Keys T.F. The clinical usefulness of the preoperative bleeding time. Arch Pathol Lab Med 1996, 120:353-356.
26. De Rossi S.S., Glick M. Bleeding time: An unreliable predictor of clinical hemostasis. J Oral Maxillofac Surg 1996, 54:1119-1120.
27. Peterson P., Hayes T.E., Arkin C.F., et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998, 133:134-139.
28. Lehman C.M., Blaylock R.C., Alexander D.P., et al. Discontinuation of the bleeding time test without detectable adverse clinical impact. Clin Chem 2001, 47:1204-1211.
29. MacDonald J.D., Remington B.J., Rodgers G.M. The skin bleeding time test as a predictor of brain bleeding time in a rat model. Thromb Res 1994, 76:535-540.
30. Vermylen J., Peerlinck K. Fatal complication of desmopressin. Lancet 1995, 346:447.
31. Stratton J., Warwicker P., Watkins S., et al. Desmopressin may be hazardous in thrombotic microangiopathy. Nephrol Dial Transplant 2001, 16:161-162.
32. Overman M., Brass E. Worsening of thrombotic thrombocytopenic purpura symptoms associated with desmopressin administration. Thromb Haemost 2004, 92:886-887.
33. Deykin D., Janson P., McMahon L. Ethanol potentiation of aspirin-induced prolongation of the bleeding time. N Engl J Med 1982, 306:852-854.
34. Quiroga T., Goycoolea M., Munoz B., et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: Comparative study in 148 patients. J Thromb Haemost 2004, 2:892-898.
35. Blajchman M.A., Lee D.H. The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes. Transfus Med Rev 1997, 11:95-105.
36. Herbert J.M., Bernat A., Maffrand J.P. Aprotinin reduces clopidogrel-induced prolongation of the bleeding time in the rat. Thromb Res 1993, 71:433-441.
37. Suzuki Y., Hillyer P., Miyamoto S., et al. Integrilin prevents prolonged bleeding times after cardiopulmonary bypass. Ann Thorac Surg 1998, 66:373-381.
38. Payne D.A., Hayes P.D., Jones C.I., et al. Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action. J Vasc Surg 2002, 35:1204-1209.
39. Wilhite D.B., Comerota A.J., Schmieder F.A., et al. Managing pad with multiple platelet inhibitors: The effect of combination therapy on bleeding time. J Vasc Surg 2003, 38:710-713.
40. Mannucci P.M. Hemostatic drugs. N Engl J Med 1998, 339:245-253.
41. Butt M.L., Shafi T., Farooqi I., et al. Effect of dialysis on bleeding time in chronic renal failure. JPMA, J Pak Med Assoc 1998, 48:242-244.
42. Edlund M., Blomback M., Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fibrinolysis 2002, 13:225-231.
43. Ulusoy S., Ovali E., Aydin F., et al. Hemostatic and fibrinolytic response to nasal desmopressin in hemodialysis patients. Med Princ Pract 2004, 13:340-345.
44. Heiden D., Mielke C.H., Rodvien R. Impairment by heparin of primary haemostasis and platelet [14c]5-hydroxytryptamine release. Br J Haematol 1977, 36:427-436.
45. Piscaglia F., Siringo S., Hermida R.C., et al. Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology 2000, 31:349-357.
46. Violi F., Leo R., Vezza E., et al. Bleeding time in patients with cirrhosis: Relation with degree of liver failure and clotting abnormalities. C.A.L.C. Group. Coagulation abnormalities in cirrh group. J Hepatol 1994, 20:531-536.
47. Hirsch D.R., Reis S.E., Polak J.F., et al. Prolonged bleeding time as a marker of venous clot lysis during streptokinase therapy. Am Heart J 1991, 122:965-971.
48. van Oeveren W., Harder M.P., Roozendaal K.J., et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990, 99:788-796. discussion 796-787.
49. Hogman M., Frostell C., Arnberg H., et al. Bleeding time prolongation and no inhalation. Lancet 1993, 341:1664-1665.
50. Noris M., Remuzzi G. Uremic bleeding: Closing the circle after 30 years of controversies?. Blood 1999, 94:2569-2574.
51. Hori N., Okanoue T., Mori T., et al. Endogenous nitric oxide production is augmented as the severity advances in patients with liver cirrhosis. Clin Exp Pharmacol Physiol 1996, 23:30-35.
52. Albornoz L., Bandi J.C., Otaso J.C., et al. Prolonged bleeding time in experimental cirrhosis: Role of nitric oxide [see comments]. J Hepatol 1999, 30:456-460.
53. Zoja C., Noris M., Corna D., et al. l-arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia. Lab Invest 1991, 65:479-483.
54. Noris M., Todeschini M., Zappella S., et al. 17betaestradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. Am J Physiol Renal Physiol 2000, 279:626-635.
55. Blajchman M.A., Bordin J.O., Bardossy L., et al. The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. Br J Haematol 1994, 86:347-350.
56. Livio M., Gotti E., Marchesi D., et al. Uraemic bleeding: Role of anaemia and beneficial effect of red cell transfusions. Lancet 1982, 2:1013-1015.
57. Moia M., Mannucci P.M., Vizzotto L., et al. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987, 2:1227-1229.
58. Li N., Hu H., Lindqvist M., et al. Platelet-leukocyte cross talk in whole blood. Arterioscler Vasc Biol 2000, 20:2702-2708.
59. Valles J., Santos M.T., Aznar J., et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998, 97:350-355.
60. Wun T., Paglieroni T., Field C.L., et al. Plateleterythrocyte adhesion in sickle cell disease. J Investig Med 1999, 47:121-127.
61. Valeri C.R., Cassidy G., Pivacek L.E., et al. Anemia-induced increase in the bleeding time: Implications for treatment of nonsurgical blood loss. Transfusion 2001, 41:977-983.
62. Sola M.C., del Vecchio A., Edwards T.J., et al. The relationship between hematocrit and bleeding time in very low birth weight infants during the first week of life. J Perinatol 2001, 21:368-371.
63. Valeri C.R., Khabbaz K., Khuri S.F., et al. Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass. J Thorac Cardiovasc Surg 1992, 104:108-116.
64. Kahn H.A., Faust G.R., Richard R., et al. Hypothermia and bleeding during abdominal aortic aneurysm repair. Ann Vasc Surg 1994, 8:6-9.
65. Valeri C.R., MacGregor H., Cassidy G., et al. Effects of temperature on bleeding time and clotting time in normal male and female volunteers. Crit Care Med 1995, 23:698-704.
66. Nilsson I.M., Magnusson S., Borchgrevink C. The Duke and Ivy methods for determination of the bleeding time. Thrombosis Diath Haemorr 1963, 10:223-234.
67. Liu Y.K., Goldstein D.M., Arora K., et al. Thigh bleeding time as a valid indicator of hemostatic competency during surgical treatment of patients with advanced renal disease. Surg Gynecol Obstet 1991, 172:269-274.
68. Zeigler Z.R. Non-occlusive bleeding times may improve the value of Ivy bleeding times. Thromb Haemost 1990, 63:371-374.
69. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000, 111:733-744.
70. Lasne D., Fiemeyer A., Chatellier G., et al. A study of platelet functions with a new analyzer using high shear stress (PFA-100) in patients undergoing coronary artery bypass graft. Throm Haemostas 2000, 84:794-799.
71. Marshall P.W., Williams A.J., Dixon R.M., et al. A comparison of the effects of aspirin on bleeding time measured using the simplate method and closure time measured using the PFA-100, in healthy volunteers. Br J Clin Pharmacol 1997, 44:151-155.
72. Quick A.J. Salicylates and bleeding: The aspirin tolerance test. American J Med Sci 1966, 252:265-269.
73. Fiore L.D., Brophy M.T., Lopez A., et al. The bleeding time response to aspirin. Identifying the hyperresponder. Am J Clin Pathol 1990, 94:292-296.
74. Rodeghiero F., Castaman G., Ruggeri M., et al. The bleeding time in normal subjects is mainly determined by platelet von Willebrand factor and is independent from blood group. Thromb Res 1992, 65:605-615.
75. Szczeklik A., Undas A., Sanak M., et al. Relationship between bleeding time, aspirin and the PLA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000, 110:965-967.
76. Mahooti S., Graesser D., Patil S., et al. PECAM-1 (CD31) expression modulates bleeding time in vivo. Am J Pathol 2000, 157:75-81.
77. Fressinaud E., Veyradier A., Truchaud F., et al. Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases. Blood 1998, 91:1325-1331.
78. Cattaneo M., Federici A.B., Lecchi A., et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999, 82:35-39.
79. Kerenyi A., Schlammadinger A., Ajzner E., et al. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function. Thromb Res 1999, 96:487-492.
80. Dean J.A., Blanchette V.S., Carcao M.D., et al. Von Willebrand disease in a pediatric-based population -comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen. Thromb Haemost 2000, 84:401-409.
81. Schlammadinger A., Kerenyi A., Muszbek L., et al. Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease. Thromb Haemost 2000, 84:88-92.
82. Wuillemin W.A., Gasser K.M., Zeerleder S.S., et al. Evaluation of a platelet function analyser (PFA-100) in patients with a bleeding tendency. Swiss Med Wkly 2002, 132:443-448.
83. Posan E., McBane R.D., Grill D.E., et al. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003, 90:483-490.
84. Cariappa R., Wilhite T.R., Parvin C.A., et al. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol 2003, 25:474-479.
85. Nitu-Whalley I.C., Lee C.A., Brown S.A., et al. The role of the platelet function analyser (PFA-100) in the characterization of patients with von Willebrand's disease and its relationships with von Willebrand factor and the ABO blood group. Haemophilia 2003, 9:298-302.
86. Koscielny J., Ziemer S., Radtke H., et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004, 10:195-204.
87. Zupan I.P., Sabovic M., Salobir B., et al. Utility of in vitro closure time test for evaluating platelet-related primary hemostasis in dialysis patients. Am J Kidney Dis 2003, 42:746-751.